Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic Factors in Advanced CRC Treated With Cetuximab
NCT01068132Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2009
- Primary completion
- Oct 2013
- Countries
- 1
- Sponsor
- Regione Lombardia
- Modality
- Monoclonal Antibodies
- Drugs
- KL-140
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in colorectal cancer (CRC), sponsored by Regione Lombardia. Primary endpoint: Progression Free Survival at 48 months. Started Apr 2009; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Cetuximab + FOLFIRI
Cetuximab 500 mg/m2 every 2 weeks + FOLFIRI
03
Who it enrols
Adult patients with histologically confirmed KRAS wild-type metastatic colorectal cancer not suitable for curative resection, with no prior chemotherapy for metastatic disease.
04
Endpoints
Primary
Progression Free Survival
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT01068132.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068132.